MCA Stability Tool

Find stability recommendations for tablets and capsules.

Product Search

Stability Notes

Store in well-filled airtight containers, protect from light.

Provenance

This compatibility recommendation is derived from Accrete D3 tablets (Internis Pharmaceuticals Ltd).

Stability Notes

Store in tightly closed containers and protect from moisture.

Provenance

This compatibility recommendation is derived from Accuretic 10mg/12.5mg tablets (Pfizer Ltd).

Stability Notes

Store in nonmetallic, airtight containers. Original packaging contains a desiccant.

Provenance

This compatibility recommendation is derived from Solvazinc 125mg effervescent tablets (Galen Ltd).

Print this list

Medicines suitable for use in MCAs, although use is likely to be off-label.  Keep medicines in MCAs for the shortest time necessary. Generally, up to 5 weeks maximum unless otherwise specified, or consider up to 8 weeks if the MCA is airtight (sealed).  Consider the risk to the individual from potency loss or dose variability, particularly with unsealed devices.  Monitor for any changes in therapeutic effect or increased adverse effects after MCA initiation.
There are concerns about stability and/or there is a lack of stability data available. These medicines can theoretically be used in MCAs, although use is likely to be off-label.  Mitigation measures may need to be considered.  Keep medicines in MCAs for the shortest time necessary.  Generally, up to 5 weeks maximum unless otherwise specified, or consider up to 8 weeks if the MCA is airtight (sealed). Consider the risk to the individual from potency loss or dose variability, particularly with unsealed devices. Monitor for any changes in therapeutic effect or increased adverse effects after MCA initiation.
Medicines under this category are not suitable for use in MCAs.
These medicines have not been reviewed by SPS.